{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:45:31Z","timestamp":1792637131920,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1007\/s11940-001-0039-0","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T18:29:09Z","timestamp":1180981749000},"page":"347-364","source":"Crossref","is-referenced-by-count":12,"title":["Psychosis due to neurologic conditions"],"prefix":"10.1007","volume":"3","author":[{"given":"David B.","family":"Arciniegas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie L.","family":"Topkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"39_CR1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.52.1.10","volume":"52","author":"EC Wolters","year":"1999","unstructured":"Wolters EC: Dopaminomimetic psychosis in Parkinson\u2019s disease patients: diagnosis and treatment. Neurology 1999, 52:S10-S13.","journal-title":"Neurology"},{"key":"39_CR2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ageing\/11.2.121","volume":"11","author":"JG Greene","year":"1982","unstructured":"Greene JG, Smith R, Gardiner M, Timbury GC: Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study. Age Ageing 1982, 11:121\u2013126.","journal-title":"Age Ageing"},{"key":"39_CR3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jnnp.55.5.377","volume":"55","author":"SE Starkstein","year":"1992","unstructured":"Starkstein SE, Mayberg HS, Leiguarda R, et al.: A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1992, 55:377\u2013382.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"39_CR4","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","volume":"43","author":"CG Goetz","year":"1993","unstructured":"Goetz CG, Stebbins GT: Risk factors for nursing home placement in advanced Parkinson\u2019s disease. Neurology 1993, 43:2227\u20132229.","journal-title":"Neurology"},{"key":"39_CR5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/089198878800100104","volume":"1","author":"EH Rubin","year":"1988","unstructured":"Rubin EH, Drevets WC, Burke WJ: The nature of psychotic symptoms in senile dementia of the Alzheimer type. J Geriatr Psychiatry Neurol 1988, 1:16\u201320.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"39_CR6","first-page":"144","volume":"5","author":"JL Cummings","year":"1992","unstructured":"Cummings JL: Psychosis in neurologic disease: neurobiology and pathogenesis. Neuropsychiatry Neuropsychol Behav Neurol 1992, 5:144\u2013150.","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"39_CR7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","volume":"47","author":"IG McKeith","year":"1996","unstructured":"McKeith IG, Galasko D, Kosaka K, et al.: Consensus guidelines for the clinical and pathologic diagnosis of dementia ith Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47:1113\u20131124.","journal-title":"Neurology"},{"key":"39_CR8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1017\/CBO9780511722110.016","volume-title":"Behavior and Mood Disorders in Focal Brain Lesions","author":"T Edwards-Lee","year":"2000","unstructured":"Edwards-Lee T, Cummings JL: Focal lesions and psychosis. In Behavior and Mood Disorders in Focal Brain Lesions. Edited by Brogousslavky J, Cummings JL. Cambridge: Cambride University Press; 2000:419\u2013436."},{"key":"39_CR9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1192\/bjp.109.458.95","volume":"109","author":"E Slater","year":"2001","unstructured":"Slater E, Beard AW, Glithero E: The schizophrenia-like psychoses of epilepsy. Br J Psychiatry 2001, 109:95\u2013150.","journal-title":"Br J Psychiatry"},{"key":"39_CR10","first-page":"41","volume-title":"Psychiatric Management in Neurological Disease","author":"ML Levy","year":"2000","unstructured":"Levy ML, Cummings JL: Parkinson\u2019s disease. In Psychiatric Management in Neurological Disease. Edited by Lauterbach EC. Washington, DC: American Psychiatric Press; 2000:41\u201370."},{"key":"39_CR11","first-page":"71","volume-title":"Psychiatric Management in Neurological Disease","author":"NG Ranen","year":"2000","unstructured":"Ranen NG: Hungington\u2019s disease. In Psychiatric Management in Neurological Disease. Edited by Lauterbach EC. Washington, DC: American Psychiatric Press; 2000:71\u201392."},{"key":"39_CR12","first-page":"93","volume-title":"Psychiatric Management in Neurological Disease","author":"EC Lauterbach","year":"2000","unstructured":"Lauterbach EC: Farh\u2019s syndrome. In Psychiatric Management in Neurological Disease. Edited by Lauterbach EC. Washington, DC: American Psychiatric Press; 2000:93\u2013136."},{"key":"39_CR13","first-page":"93","volume-title":"Psychiatric Management in Neurological Disease","author":"EC Lauterbach","year":"2000","unstructured":"Lauterbach EC: Wilson\u2019s disease (progressive hepatlenticular degeneration). In Psychiatric Management in Neurological Disease. Edited by Lauterbach EC. Washington, DC: American Psychiatric Press; 2000:93\u2013136."},{"key":"39_CR14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mds.870120403","volume":"12","author":"SA Factor","year":"1997","unstructured":"Factor SA, Friedman JH: The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997, 12:483\u2013496.","journal-title":"Mov Disord"},{"key":"39_CR15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/jnnp.45.12.1161","volume":"45","author":"Y Smet de","year":"1982","unstructured":"de Smet Y, Ruberg M, Serdaru M, et al.: Confusion, dementia and anticholinergics in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1982, 45:1161\u20131164.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"39_CR16","first-page":"703","volume":"60","author":"P Greene","year":"1993","unstructured":"Greene P, Cote L, Fahn S: Treatment of drug-induced psychosis in Parkinson\u2019s disease with clozapine. Adv Neurol 1993, 60:703\u2013706.","journal-title":"Adv Neurol"},{"key":"39_CR17","first-page":"54","volume":"60","author":"LS Schneider","year":"1999","unstructured":"Schneider LS: Pharmacologic management of psychosis in dementia. J Clin Psychiatry 1999, 60(suppl)8:54\u201360.","journal-title":"J Clin Psychiatry"},{"key":"39_CR18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/(SICI)1099-1166(200003)15:3<280::AID-GPS108>3.0.CO;2-N","volume":"15","author":"E Fergusson","year":"2000","unstructured":"Fergusson E, Howard R: Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry 2000, 15:280\u2013281.","journal-title":"Int J Geriatr Psychiatry"},{"key":"39_CR19","volume-title":"Textbook of Neuropsychiatry","author":"KE White","year":"1997","unstructured":"White KE, Cummings JL: Neuropsychatric aspects of Alzheimer\u2019s disease and other dementing illnesses. In Textbook of Neuropsychiatry, 3rd ed. Edited by Yudofsky SC, Hales RE. Washington, DC: American Psychiatric Press; 1997.","edition":"3rd ed"},{"key":"39_CR20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/archneur.1991.00530180075020","volume":"48","author":"GS Zubenko","year":"1991","unstructured":"Zubenko GS, Moossy J, Martinez AJ, et al.: Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991, 48:619\u2013624.","journal-title":"Arch Neurol"},{"key":"39_CR21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0006-3223(95)00035-F","volume":"37","author":"BA Lawlor","year":"1995","unstructured":"Lawlor BA, Ryan TM, Bierer LM, et al.: Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer\u2019s disease. Biol Psychiatry 1995, 37:895\u2013896.","journal-title":"Biol Psychiatry"},{"key":"39_CR22","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1523\/JNEUROSCI.17-14-05573.1997","volume":"17","author":"A Russo-Neustadt","year":"1997","unstructured":"Russo-Neustadt A, Cotman CW: Adrenergic receptors in Alzheimer\u2019s disease brain: selective increases in the cerebella of aggressive patients. J Neurosci 1997, 17:5573\u20135580.","journal-title":"J Neurosci"},{"key":"39_CR23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1176\/ajp.149.4.443","volume":"149","author":"JL Cummings","year":"1992","unstructured":"Cummings JL: Depression and Parkinson\u2019s disease: a review. Am J Psychiatry 1992, 149:443\u2013454.","journal-title":"Am J Psychiatry"},{"key":"39_CR24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/jnnp.50.2.183","volume":"50","author":"HS Levin","year":"1987","unstructured":"Levin HS, High WM, Goethe KE, et al.: The neurobehavioral rating scale: assessment of the behavioural sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry 1987, 50:183\u2013193.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"39_CR25","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199911253412207","volume":"341","author":"R Mayeux","year":"1999","unstructured":"Mayeux R, Sano M: Drug therapy: treatment of Alzheimer\u2019s disease. N Engl J Med 1999, 341:1670\u20131679.","journal-title":"N Engl J Med"},{"key":"39_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1592\/phco.20.1.23.34661","volume":"20","author":"JL Defilippi","year":"2000","unstructured":"Defilippi JL, Crismon ML: Antipsychotic agents in patients with dementia. Pharmacotherapy 2000, 20:23\u201333. This is an excellent review of the evaluation and treatment of secondary psychoses in Alzheimer\u2019s disease, and offers a treatment algorithm for the treatment of such that neurologists, neuropsychiatrists, and psychiatrists may find extremely useful.","journal-title":"Pharmacotherapy"},{"key":"39_CR27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199903113401011","volume":"340","author":"JL Cummings","year":"1999","unstructured":"Cummings JL: Managing psychosis in patients with Parkinson\u2019s disease. N Engl J Med 1999, 340:801\u2013803.","journal-title":"N Engl J Med"},{"key":"39_CR28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","volume":"15","author":"JH Friedman","year":"2000","unstructured":"Friedman JH, Factor SA: Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson\u2019s disease. Mov Disord 2000, 15:201\u2013211. This is an excellent review of the evaluation and treatment of secondary psychoses in Parkinson\u2019s disease. This paper summarizes the available literature on all the use of antipsychotics and offers practical treatment guidelines.","journal-title":"Mov Disord"},{"key":"39_CR29","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1528-1157.1999.tb00883.x","volume":"40","author":"R Torta","year":"1999","unstructured":"Torta R, Keller R: Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999, 40:S2-S20. This is an excellent review of the evaluation and treatment of psychosis in epilepsy. The article describes the phenomenology and neurobiology of interictal psychoses, and reviews the mechanisms by which maximizing anticonvulsant therapy may afford improvement of these conditions.","journal-title":"Epilepsia"},{"key":"39_CR30","first-page":"5","volume-title":"Movement Disorders in Neurology and Neuropsychiatry","author":"LG Miller","year":"1999","unstructured":"Miller LG, Jankovic J: Drug-induced dyskinesias: an overview. In Movement Disorders in Neurology and Neuropsychiatry, edn 2. Edited by Joseph AB, Young RR. Oxford: Blackwell Science, Inc.; 1999:5\u201330.","edition":"edn 2"},{"key":"39_CR31","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1176\/ajp.155.11.1512","volume":"155","author":"DP Devanand","year":"1998","unstructured":"Devanand DP, Marder K, Michaels KS, et al.: A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer\u2019s disease. Am J Psychiatry 1998, 155:1512\u20131520.","journal-title":"Am J Psychiatry"},{"key":"39_CR32","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/bmj.305.6855.673","volume":"305","author":"IG McKeith","year":"1992","unstructured":"McKeith IG, Fairbairn A, Perry R, et al.: Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br Med J 1992, 305:673\u2013678.","journal-title":"Br Med J"},{"key":"39_CR33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mds.870120423","volume":"12","author":"G Meco","year":"1997","unstructured":"Meco G, Alessandri A, Giustini P, Bonifati V: Risperidone in levodopa-induced psychosis in advanced Parkinson\u2019s disease: an open-label, long-term study. Mov Disord 1997, 12:610\u2013612.","journal-title":"Mov Disord"},{"key":"39_CR34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/1531-8257(200003)15:2<301::AID-MDS1014>3.0.CO;2-2","volume":"15","author":"NA Leopold","year":"2000","unstructured":"Leopold NA: Risperidone treatment of drug-related psychosis in patients with Parkinsonism. Mov Disord 2000, 15:301\u2013304.","journal-title":"Mov Disord"},{"key":"39_CR35","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1176\/jnp.9.4.594","volume":"9","author":"RH Workman","year":"1997","unstructured":"Workman RH, Orengo CA, Bakey AA, et al.: The use of risperidone for psychosis and agitation in demented patients with Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci 1997, 9:594\u2013597.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"39_CR36","first-page":"556","volume":"56","author":"SS Rich","year":"1995","unstructured":"Rich SS, Friedman JH, Ott BR: Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson\u2019s disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995, 56:556\u2013559.","journal-title":"J Clin Psychiatry"},{"key":"39_CR37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00004850-199811000-00006","volume":"13","author":"S Schreiber","year":"1998","unstructured":"Schreiber S, Klag E, Gross Y, et al.: Beneficial effect of risperidone on sleep distrurbance and psychosis following traumatic brain injury. Int Clin Psychopharmacol 1998, 13:273\u2013275.","journal-title":"Int Clin Psychopharmacol"},{"key":"39_CR38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00004714-199704000-00021","volume":"17","author":"AP Popli","year":"1997","unstructured":"Popli AP: Risperidone for the treatment of psychosis associated with neurosarcoidosis. J Clin Psychopharmacol 1997, 17:132\u2013133.","journal-title":"J Clin Psychopharmacol"},{"key":"39_CR39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-199902000-00020","volume":"19","author":"C Dallocchio","year":"1999","unstructured":"Dallocchio C, Buffa C, Tinelli C, Mazzarello P: Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 1999, 19:101\u2013103.","journal-title":"J Clin Psychopharmacol"},{"key":"39_CR40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0140-6736(95)92307-1","volume":"346","author":"IG McKeith","year":"1995","unstructured":"McKeith IG, Ballard CG, Harrison RWS: Neuroleptic sensitivity to risperidone in Lewy Body dementia. Lancet 1995, 346:699.","journal-title":"Lancet"},{"key":"39_CR41","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","volume":"57","author":"JS Street","year":"2000","unstructured":"Street JS, Clark WS, Gannon KS, et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000, 57:968\u2013976.","journal-title":"Arch Gen Psychiatry"},{"key":"39_CR42","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.47.4.1085","volume":"47","author":"EC Wolters","year":"1996","unstructured":"Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson\u2019s disease. Neurology 1996, 47:1085\u20131087.","journal-title":"Neurology"},{"key":"39_CR43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1176\/jnp.11.3.392","volume":"11","author":"D Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Lim NG, Tandberg E: Olanzapine for psychosis in patients with Parkinson\u2019s disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999, 11:392\u2013394.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"39_CR44","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9","volume":"14","author":"ES Molho","year":"1999","unstructured":"Molho ES, Factor SA: Worsening of motor features of Parkinsonism with olanzapine. Mov Disord 1999, 14:1014\u20131016.","journal-title":"Mov Disord"},{"key":"39_CR45","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/jnnp.65.5.774","volume":"65","author":"JM Graham","year":"1998","unstructured":"Graham JM, Sussman JD, Ford KS, Sagar HJ: Olanzapine in the treatment of hallucinosis in idiopathic Parkinson\u2019s disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998, 65:774\u2013777.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"39_CR46","first-page":"285","volume":"21","author":"JH Friedman","year":"1998","unstructured":"Friedman JH, Goldstein S, Jacques C: Substituting clozapine for olanzapine in psychiatrically stable Parkinson\u2019s disease patients: results of an open label pilot study. Clin Neuropharmacol 1998, 21:285\u2013288.","journal-title":"Clin Neuropharmacol"},{"key":"39_CR47","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/(SICI)1099-1166(199906)14:6<459::AID-GPS957>3.0.CO;2-R","volume":"14","author":"Z Walker","year":"1999","unstructured":"Walker Z, Grace J, Overshot R, et al.: Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999, 14:459\u2013466.","journal-title":"Int J Geriatr Psychiatry"},{"key":"39_CR48","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM200009283431316","volume":"343","author":"VE Grove","year":"2000","unstructured":"Grove VE, Quintanilla J, DeVaney GT: Improvement of Huntington\u2019s disease with olanzapine and valproate. N Engl J Med 2000, 343:973\u2013974.","journal-title":"N Engl J Med"},{"key":"39_CR49","volume-title":"Quetiapine may reduce hostility in patients with psychoses related Alzheimer\u2019s disease. Abstracts of the International Congress on Schizophrenia Research biennial meeting 1999","author":"L Schneider","year":"1999","unstructured":"Schneider L, Yeung P, Sweitzer D, Arvanitis L: Quetiapine may reduce hostility in patients with psychoses related Alzheimer\u2019s disease. Abstracts of the International Congress on Schizophrenia Research biennial meeting 1999. Santa Fe: International Congress on Schizophrenia; 1999."},{"key":"39_CR50","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4088\/JCP.v60n0504","volume":"60","author":"DQ McManus","year":"1999","unstructured":"McManus DQ, Arvanitis LA, Kowalcyk BB: Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999, 60:292\u2013298.","journal-title":"J Clin Psychiatry"},{"key":"39_CR51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00004714-200002000-00010","volume":"20","author":"SD Targum","year":"2000","unstructured":"Targum SD, Abbott JL: Efficacy of quetiapine in Parkinson\u2019s patients with psychosis. J Clin Psychopharmacol 2000, 20:54\u201360.","journal-title":"J Clin Psychopharmacol"},{"key":"39_CR52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10401239909147063","volume":"11","author":"MM Menza","year":"1999","unstructured":"Menza MM, Palermo B, Mark M: Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson\u2019s disease. Ann Clin Psychiatry 1999, 11:141\u2013144.","journal-title":"Ann Clin Psychiatry"},{"key":"39_CR53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/jnp.10.2.216","volume":"10","author":"MA Parsa","year":"1998","unstructured":"Parsa MA, Bastani B: Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci 1998, 10:216\u2013219.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"39_CR54","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/1531-8257(200005)15:3<579::AID-MDS1024>3.0.CO;2-0","volume":"15","author":"HH Fernandez","year":"2000","unstructured":"Fernandez HH, Lannon MC, Friedman JH, Abbott BP: Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. Mov Disord 2000, 15:579\u2013581.","journal-title":"Mov Disord"},{"key":"39_CR55","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","volume":"353","author":"The French Clozapine Parkinson Study Group","year":"1999","unstructured":"The French Clozapine Parkinson Study Group: Clozapine in drug-induced psychosis in Parkinson\u2019s disease. Lancet 1999, 353:2041\u20132042.","journal-title":"Lancet"},{"key":"39_CR56","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"The Parkinson Study Group","year":"1999","unstructured":"The Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med 1999, 340:757\u2013763.","journal-title":"N Engl J Med"},{"key":"39_CR57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/070674379704200125","volume":"42","author":"SA Chong","year":"1997","unstructured":"Chong SA, Ko SM: Clozapine treatment of psychosis associated with multiple sclerosis. Can J Psychiatry 1997, 42:90\u201391.","journal-title":"Can J Psychiatry"},{"key":"39_CR58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1600-0447.1990.tb05297.x","volume":"82","author":"T Lewander","year":"1990","unstructured":"Lewander T, Westerbergh SE, Morrison D: Clinical profile of remoxipride-a combined analysis of a comparative double-blind multicentre trial program. Acta Psychiatrica Scandinavica 1990, 82:92\u201398.","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"39_CR59","first-page":"135","volume":"17","author":"YD Lapierre","year":"1992","unstructured":"Lapierre YD, Ancill R, Awad G, et al.: A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. J Psychiatry Neurosci 1992, 17:135\u2013145.","journal-title":"J Psychiatry Neurosci"},{"key":"39_CR60","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","volume":"45","author":"J Zoldan","year":"1995","unstructured":"Zoldan J, Friedberg G, Livneh M, Melamed E: Psychosis in advanced Parkinson\u2019s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995, 45:1305\u20131308.","journal-title":"Neurology"},{"key":"39_CR61","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archpsyc.1991.01810360077011","volume":"48","author":"SE Molchan","year":"1991","unstructured":"Molchan SE, Vitiello B, Minichiello M, Sunderland T: Reciprocal changes in psychosis and mood after physostigmine in a patient with Alzheimer\u2019s disease. Arch Gen Psychiatry 1991, 48:1113\u20131114.","journal-title":"Arch Gen Psychiatry"},{"key":"39_CR62","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0006-3223(93)90009-3","volume":"33","author":"JL Cummings","year":"1993","unstructured":"Cummings JL, Gorman DG, Shapira J: Physostigmine ameliorates the delusions of Alzheimer\u2019s disease. Biol Psychiatry 1993, 33:536\u2013541.","journal-title":"Biol Psychiatry"},{"key":"39_CR63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1176\/jnp.10.1.55","volume":"10","author":"D Kaufer","year":"1998","unstructured":"Kaufer D, Cummings JL, Christine D: Differential neuropsychiatric symptom responses to tacrine in Alzheimer\u2019s disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998, 10:55\u201363.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"39_CR64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000052760","volume":"45","author":"ML Levy","year":"1999","unstructured":"Levy ML, Cummings JL, Kahn-Rose R: Neuropsychiatric symptoms and cholinergic therapy for Alzheimer\u2019s disease. Gerontology 1999, 45(suppl):15\u201322.","journal-title":"Gerontology"},{"key":"39_CR65","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S1041610298005341","volume":"10","author":"C Shea","year":"1998","unstructured":"Shea C, MacKnight C, Rockwood K: Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. International Psychogeriatrics 1998, 10:229\u2013238.","journal-title":"International Psychogeriatrics"},{"key":"39_CR66","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/(SICI)1099-1166(200005)15:5<387::AID-GPS131>3.0.CO;2-9","volume":"15","author":"IG McKeith","year":"2000","unstructured":"McKeith IG, Grace JB, Walker Z, et al.: Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000, 15:387\u2013392.","journal-title":"Int J Geriatr Psychiatry"},{"key":"39_CR67","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1212\/WNL.50.5.1222","volume":"50","author":"JC Morris","year":"1998","unstructured":"Morris JC, Cyrus PA, Orazem J, et al.: Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer\u2019s disease. Neurology 1998, 50:1222\u20131230.","journal-title":"Neurology"},{"key":"39_CR68","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/070674379103600522","volume":"36","author":"SF Signer","year":"1991","unstructured":"Signer SF, Krelina M: Hallucinations controlled with anticonvulsants. Can J Psychiatry 1991, 36:388\u2013389.","journal-title":"Can J Psychiatry"},{"key":"39_CR69","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/00048679809065540","volume":"32","author":"T Terao","year":"1998","unstructured":"Terao T, Tani Y: Carbamazepine treatment in a case of musical hallucinations with temporal lobe abnormalities. Aust N Z J Psychiatry 1998, 32:454\u2013456.","journal-title":"Aust N Z J Psychiatry"},{"key":"39_CR70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00004850-200015020-00009","volume":"15","author":"H Hori","year":"2000","unstructured":"Hori H, Terao T, Shiraishi Y, Nakamura J: Treatment of Charles Bonnet syndrome with valproate. Int Clin Psychopharmacol 2000, 15:117\u2013119.","journal-title":"Int Clin Psychopharmacol"},{"key":"39_CR71","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1176\/jnp.7.3.304","volume":"7","author":"SA Factor","year":"1995","unstructured":"Factor SA, Molho ES, Brown DL: Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci 1995, 7:304\u2013307.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"39_CR72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1017\/S0317167100027141","volume":"15","author":"TA Hurwitz","year":"1988","unstructured":"Hurwitz TA, Calne DB, Waterman K: Treatment of dopaminominetic psychosis in Parkinson\u2019s disease with electroconvulsive therapy. Can J Neurol Sci 1988, 15:32\u201334.","journal-title":"Can J Neurol Sci"},{"key":"39_CR73","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ana.410310320","volume":"31","author":"PF Renshaw","year":"1992","unstructured":"Renshaw PF, Stern TA, Welch C, et al.: Electroconvulsive therapy treatment of depression in a patient with adult GM2 gangliosidosis. Ann Neurol 1992, 31:342\u2013344.","journal-title":"Ann Neurol"},{"key":"39_CR74","first-page":"37","volume":"57","author":"PV Rabins","year":"1996","unstructured":"Rabins PV: Developing treatment guidelines for Alzheimer\u2019s disease and other dementias. J Clin Psychiatry 1996, 57(suppl):37\u201338.","journal-title":"J Clin Psychiatry"},{"key":"39_CR75","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0897-1897(95)80590-7","volume":"8","author":"S Boehm","year":"1995","unstructured":"Boehm S, Whall AL, Cosgrove KL, et al.: Behavioral analysis and nursing interventions for reducing disruptive behaviors of patients with dementia. Appl Nurs Res 1995, 8:118\u2013122.","journal-title":"Appl Nurs Res"},{"key":"39_CR76","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00002093-199404000-00014","volume":"8","author":"K Maslow","year":"1994","unstructured":"Maslow K: Special care units for persons with dementia: expected and observed effects on behavioral symptoms. Alzheimer Dis Assoc Disord 1994, 8(suppl):122\u2013137.","journal-title":"Alzheimer Dis Assoc Disord"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0039-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-001-0039-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0039-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:03:02Z","timestamp":1683867782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-001-0039-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1007\/s11940-001-0039-0","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}